Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine

References

• LiptonRBBigalMEMigraine: epidemiology, impact, and risk factors for progressionHeadache200545 suppl 1S31315833088
   PubMed Web of Science ®Google Scholar
• IHSThe International Classification of Headache Disorders: 2nd editionCephalalgia200424 suppl 1916014979299
   PubMed Web of Science ®Google Scholar
• OlesenJBousserMGDienerHCNew appendix criteria open for a broader concept of chronic migraineCephalalgia200626674274616686915
   PubMed Web of Science ®Google Scholar
• ManackANBuseDCLiptonRBChronic migraine: epidemiology and disease burdenCurr Pain Headache Rep2011151707821063918
   PubMed Web of Science ®Google Scholar
• SilbersteinSDTreatment recommendations for migraineNat Clin Pract Neurol20084948248918665146
   PubMedGoogle Scholar
• BinderWJBrinMFBlitzerAPogodaJMBotulinum toxin type A (BOTOX) for treatment of migraineSemin Cutan Med Surg20012029310011474749
   PubMed Web of Science ®Google Scholar
• BinderWJBrinMFBlitzerABotulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label studyOtolaryngol Head Neck Surg2000123666967611112955
   PubMed Web of Science ®Google Scholar
• BinderWJBlitzerABrinMFTreatment of hyperfunctional lines of the face with botulinum toxin ADermatol Surg19982411119812059834739
   PubMed Web of Science ®Google Scholar
• DresslerDBeneckeRPharmacology of therapeutic botulinum toxin preparationsDisabil Rehabil200729231761176818033601
   PubMed Web of Science ®Google Scholar
• AktoriesKBarmannMOhishiIBotulinum C2 toxin ADP-ribosylates actinNature198632260773903923736664
   PubMed Web of Science ®Google Scholar
• BhidayasiriRTruongDDExpanding use of botulinum toxinJ Neurol Sci1520052351–219
   Google Scholar
• SampaioCCostaJFerreiraJJClinical comparability of marketed formulations of botulinum toxinMov Disord200419 suppl 8S12913615027065
   PubMed Web of Science ®Google Scholar
• FDA UFDA gives update on botulinum toxin safety warnings; established names of drugs changedFDA News Release
   Google Scholar
• AlbaneseATerminology for preparations of botulinum neurotoxins: what a difference a name makesJama20113051899021205970
   PubMed Web of Science ®Google Scholar
• FrevertJDresslerDComplexing proteins in botulinum toxin type A drugs: a help or a hindranceBiologics2010432533221209727
   PubMedGoogle Scholar
• ForanPGMohammedNLiskGOEvaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neuronsJ Biol Chem200327821363137112381720
   PubMed Web of Science ®Google Scholar
• RosalesRLBigalkeHDresslerDPharmacology of botulinum toxin: differences between type A preparationsEur J Neurol200613 suppl 121016417591
   PubMed Web of Science ®Google Scholar
• DollyJOLawrenceGWMengJNeuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeuticsCurr Opin Pharmacol20099332633519394272
   PubMed Web of Science ®Google Scholar
• BrinMFFahnSMoskowitzCLocalized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasmAdv Neurol1988505996083400513
   PubMedGoogle Scholar
• EleopraRTugnoliVDe GrandisDThe variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in humansMov Disord199712189948990059
   PubMed Web of Science ®Google Scholar
• FrassonEPrioriARuzzanteBNerve stimulation boosts botulinum toxin action in spasticityMov Disord200520562462915726575
   PubMed Web of Science ®Google Scholar
• WeyJJTangSSWuTYDisulfide bond reduction corresponds to dimerization and hydrophobi-city changes of Clostridium botulinum type A neurotoxinActa Pharmacol Sin20062791238124616923346
   PubMed Web of Science ®Google Scholar
• ForanPGDavletovBMeunierFAGetting muscles moving again after botulinum toxin: novel therapeutic challengesTrends Mol Med20039729129912900216
   PubMed Web of Science ®Google Scholar
• DollyJOAokiKRThe structure and mode of action of different botulinum toxinsEur J Neurol200613 suppl 41917112344
   PubMed Web of Science ®Google Scholar
• MeunierFASchiavoGMolgoJBotulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmissionJ Physiol Paris2002961–210511311755789
   PubMedGoogle Scholar
• BrinMFBotulinum toxin: chemistry, pharmacology, toxicity, and immunologyMuscle Nerve Suppl19976S1461689826987
   PubMedGoogle Scholar
• AokiKRReview of a proposed mechanism for the antinociceptive action of botulinum toxin type ANeurotoxicology200526578579316002144
   PubMed Web of Science ®Google Scholar
• PavoneFLuvisettoSBotulinum neurotoxin for pain management: insights from animal modelsToxins201022890291322069581
   PubMed Web of Science ®Google Scholar
• MenseSNeurobiological basis for the use of botulinum toxin in pain therapyJ Neurol2004251 suppl 1I1714991335
   PubMed Web of Science ®Google Scholar
• ArezzoJCPossible mechanisms for the effects of botulinum toxin on painClin J Pain2002186 supplS12513212569959
   PubMed Web of Science ®Google Scholar
• WelchMJPurkissJRFosterKASensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxinsToxicon200038224525810665805
   PubMed Web of Science ®Google Scholar
• DurhamPLCadyRRegulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapyHeadache20044413542 discussion 42–3314979881
   PubMed Web of Science ®Google Scholar
• CuiMKhanijouSRubinoJAokiKRSubcutaneous administration of botulinum toxin A reduces formalin-induced painPain120041071–212513314715398
   PubMed Web of Science ®Google Scholar
• BlerschWSchulte-MattlerWJPrzywaraSBotulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized studyJ Neurol Sci20022051596312409185
   PubMed Web of Science ®Google Scholar
• Bach-RojeckyLLackovicZAntinociceptive effect of botulinum toxin type a in rat model of carrageenan and capsaicin induced painCroat Med J200546220120815849840
   PubMed Web of Science ®Google Scholar
• Bach-RojeckyLReljaMLackovicZBotulinum toxin type A in experimental neuropathic painJ Neural Transm2005112221521915657640
   PubMed Web of Science ®Google Scholar
• MarinelliSLuvisettoSCobianchiSBotulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal modelsNeuroscience2010171131632820826198
   PubMed Web of Science ®Google Scholar
• MikaJRojewskaEMakuchWThe effect of botulinum neurotoxin A on sciatic nerve injury-induced neuroimmunological changes in rat dorsal root ganglia and spinal cordNeuroscience201117535836621111791
   PubMed Web of Science ®Google Scholar
• RanouxDAttalNMorainFBouhassiraDBotulinum toxin type A induces direct analgesic effects in chronic neuropathic painAnn Neurol200864327428318546285
   PubMed Web of Science ®Google Scholar
• Favre-GuilmardCAuguetMChabrierPEDifferent antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat modelsEur J Pharmacol20096171–3485319576881
   PubMed Web of Science ®Google Scholar
• Bach-RojeckyLSalkovic-PetrisicMLackovicZBotulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injectionEur J Pharmacol20106331–3101420123097
   PubMed Web of Science ®Google Scholar
• CaleoMAntonucciFRestaniLMazzocchioRA reappraisal of the central effects of botulinum neurotoxin type A: by what mechanism?J Neurochem20091091152419154335
   PubMed Web of Science ®Google Scholar
• KitamuraYMatsukaYSpigelmanIBotulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constrictionNeuroscience200915941422142919409226
   PubMed Web of Science ®Google Scholar
• CaleoMSchiavoGCentral effects of tetanus and botulinum neurotoxinsToxicon10200954559359919264088
   PubMed Web of Science ®Google Scholar
• AntonucciFRossiCGianfranceschiLLong-distance retrograde effects of botulinum neurotoxin AJ Neurosci200828143689369618385327
   PubMed Web of Science ®Google Scholar
• MatakIBach-RojeckyLFilipovicBLackovicZBehavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin ANeuroscience201118620120721539899
   PubMed Web of Science ®Google Scholar
• SilbersteinSMathewNSaperJJenkinsSBotulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research GroupHeadache200040644545010849039
   PubMed Web of Science ®Google Scholar
• EversSVollmer-HaaseJSchwaagSBotulinum toxin A in the prophylactic treatment of migraine – a randomized, double-blind, placebo-controlled studyCephalalgia2004241083884315377314
   PubMed Web of Science ®Google Scholar
• ElkindAHO’CarrollPBlumenfeldAA series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxisJ Pain200671068869617018329
   PubMed Web of Science ®Google Scholar
• AuroraSKGawelMBrandesJLBotulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo- controlled exploratory studyHeadache200747448649917445098
   PubMed Web of Science ®Google Scholar
• AnandKSPrasadASinghMMBotulinum toxin type A in prophylactic treatment of migraineAm J Ther200613318318716772757
   PubMedGoogle Scholar
• VoAHSatoriRJabbariBBotulinum toxin type-a in the prevention of migraine: a double-blind controlled trialAviat Space Environ Med2007785 supplB11311817547312
   PubMedGoogle Scholar
• FreitagFGDiamondSDiamondMUrbanGBotulinum toxin type A in the treatment of chronic migraine without medication overuseHeadache200848220120918042229
   PubMed Web of Science ®Google Scholar
• ReljaMPooleACSchoenenJA multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headachesCephalalgia200727649250317428299
   PubMed Web of Science ®Google Scholar
• SaperJRMathewNTLoderEWA double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migrainePain Med20078647848517716321
   PubMed Web of Science ®Google Scholar
• AuroraSKDodickDWTurkelCCOnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trialCephalalgia201030779380320647170
   PubMed Web of Science ®Google Scholar
• DienerHCDodickDWAuroraSKOnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trialCephalalgia201030780481420647171
   PubMed Web of Science ®Google Scholar
• ChanVWMcCabeEJMacGregorDLBotox treatment for migraine and chronic daily headache in adolescentsJ Neurosci Nurs200941523524319835236
   PubMed Web of Science ®Google Scholar
• AhmedKOasKHMackKJGarzaIExperience with botulinum toxin type A in medically intractable pediatric chronic daily headachePediatr Neurol201043531631920933173
   PubMed Web of Science ®Google Scholar
• MathewNTFrishbergBMGawelMBotulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trialHeadache200545429330715836565
   PubMed Web of Science ®Google Scholar
• NaumannMSoYArgoffCEAssessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyNeurology200870191707171418458231
   PubMed Web of Science ®Google Scholar
• DodickDWTurkelCCDegryseREOnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical programHeadache20105069213619925625
   PubMed Web of Science ®Google Scholar
• GarzaISchwedtTJChronic migraineUpToDate, Wolters Kluwer Health2011 Desktop 19.1Accessed June 18, 2011
   Google Scholar
• MathewNTJaffriSFA double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot studyHeadache200949101466147819912346
   PubMed Web of Science ®Google Scholar
• RahimtoolaHBuurmaHTijssenCCMigraine prophylactic medication usage patterns in The NetherlandsCephalalgia200323429330112716348
   PubMed Web of Science ®Google Scholar
• CadyRSchreiberCBotulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issuesHeadache200848690091318047501
   PubMed Web of Science ®Google Scholar
• OndoWGVuongKDDermanHSBotulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design studyCephalalgia2004241606514687015
   PubMed Web of Science ®Google Scholar
• SilbersteinSDStarkSRLucasSMBotulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trialMayo Clin Proc20058091126113716178492
   PubMed Web of Science ®Google Scholar
• SilbersteinSDStarkSRLucasSMBotulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clinic proceedingsMayo Clinic9200580911261137
   PubMed Web of Science ®Google Scholar
• AllerganBotox/Botox Cosmetic package insert:17
   Google Scholar
• WoodcockJResponse to citizen petition on botulinum toxin (Docket No. FDA-2008-P-0061)FDA2009
   Google Scholar
• BlumenfeldAMSchimJDChippendaleTJBotulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraineHeadache200848221022018047502
   PubMed Web of Science ®Google Scholar
• MagalhaesEMenezesCCardealMMeloABotulinum toxin type A versus amitriptyline for the treatment of chronic daily migraineClin Neurol Neurosurg2010112646346620399553
   PubMed Web of Science ®Google Scholar
• CadyRKSchreiberCPPorterJAA multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraineHeadache2011511213221070228
   PubMed Web of Science ®Google Scholar
• BlumenfeldASilbersteinSDDodickDWMethod of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical programHeadache20105091406141820958294
   PubMed Web of Science ®Google Scholar
• GerwinRTreatment of chronic migraine headache with onabotulinumtoxinACurr Pain Headache Rep201115533633821547527
   PubMed Web of Science ®Google Scholar